2017-07-30T04:38:15+03:00[Europe/Moscow] en true Miltefosine, Idelalisib, Piceatannol, Enzastaurin, Genistein, Alvocidib, Brigatinib, AEE788, VX-680, ZM447439, Momelotinib, TG101348, Lenvatinib, Miyabenol C, SU6656, Dinaciclib, Tivantinib, Abemaciclib, BIM-1, U0126, Calphostin C, K252a, KT5720, Midostaurin, Ro-318220, Stauprimide, Y-27632, Volasertib, SB-431542, Hesperadin, Seliciclib, Losmapimod, Fasudil, Ceritinib, Linsitinib, Ripasudil, Binimetinib, Palbociclib, Staurosporine, PP2 (kinase inhibitor), Masitinib, Balanol, Cobimetinib, H-89, Alisertib flashcards
Protein kinase inhibitors

Protein kinase inhibitors

  • Miltefosine
    Miltefosine (trade names Impavido and Miltex) is a broad-spectrum phospholipid antimicrobial drug.
  • Idelalisib
    Idelalisib (trade name Zydelig zye-DEL-ig, codenamed GS-1101 or CAL-101) is a drug used for the treatment of certain hematological malignancies.
  • Piceatannol
    Piceatannol is a stilbenoid, a type of phenolic compound.
  • Enzastaurin
    Enzastaurin is a synthetic bisindolylmaleimide with potential antineoplastic activity.
  • Genistein
    Genistein is an angiogenesis inhibitor and a phytoestrogen and belongs to the category of isoflavones.
  • Alvocidib
    Alvocidib (INN; also known as Flavopiridol or HMR-1275) is a flavonoid alkaloid CDK9 kinase inhibitor under clinical development for the treatment of acute myeloid leukemia, by Tolero Pharmaceuticals, Inc.
  • Brigatinib
    Brigatinib (previously known as AP26113) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc.
  • AEE788
    AEE788 is a multitargeted human epidermal receptor (HER) 1/2 and vascular endothelial growth factor receptor (VEGFR) 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1.
  • VX-680
    VX-680 is an aurora inhibitor.
  • ZM447439
    ZM447439 is an aurora inhibitor.
  • Momelotinib
    Momelotinib (INN, formerly GS-0387, CYT-387) is an inhibitor of Janus kinases JAK1 and JAK2, acting as an ATP competitor with IC50 values of 11 and 18 nM, respectively.
  • TG101348
    TG101348 (SAR302503) is an orally available inhibitor of Janus kinase 2 (JAK-2) developed for the treatment of patients with myeloproliferative diseases including myelofibrosis.
  • Lenvatinib
    Lenvatinib (trade name Lenvima) is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well.
  • Miyabenol C
    Miyabenol C is a stilbenoid.
  • SU6656
    SU6656 is a Src family kinase inhibitor developed by the biotechnology company SUGEN Inc (a subsidiary of Pharmacia) in 2000.
  • Dinaciclib
    Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs).
  • Tivantinib
    Tivantinib (ARQ197; by Arqule, Inc.) is an experimental anti-cancer drug.
  • Abemaciclib
    Abemaciclib (previously known as LY2835219) is a CDK inhibitor selective for CDK4 and CDK6.
  • BIM-1
    BIM-1 and the related compounds BIM-2, BIM-3, and BIM-8 are bisindolylmaleimide-based protein kinase C (PKC) inhibitors.
  • U0126
    U0126 is a highly selective inhibitor of both MEK1 and MEK2, a type of MAPK/ERK kinase.
  • Calphostin C
    Calphostin C is a natural chemical compound.
  • K252a
    K252a is an alkaloid isolated from Nocardiopisis sp.
  • KT5720
    KT5720 is a kinase inhibitor with specificity towards protein kinase A.
  • Midostaurin
    Midostaurin (PKC412) is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
  • Ro-318220
    Ro-318220 is a protein kinase C (PKC) inhibitor of the bisindolylmaleimide class.
  • Stauprimide
    Stauprimide is a semi-synthetic analog of the staurosporine family of indolocarbazoles.
  • Y-27632
    Y-27632 is a biochemical tool used in the study of the rho-associated protein kinase (ROCK) signaling pathways.
  • Volasertib
    Volasertib (also known as BI 6727) is a small molecule inhibitor of the PLK1 (polo-like kinase 1) protein being developed by Boehringer Ingelheim for use as an anti-cancer agent.
  • SB-431542
    SB-431542 is a drug candidate developed by GlaxoSmithKline (GSK) as an inhibitor of the activin receptor-like kinase (ALK) receptors, ALK5, ALK4 and ALK7.
  • Hesperadin
    Hesperadin is an aurora kinase inhibitor.
  • Seliciclib
    Seliciclib (roscovitine or CYC202) is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells.
  • Losmapimod
    Losmapimod (GW856553X) is a drug developed by GlaxoSmithKline which acts as a selective inhibitor of the enzyme family known as p38 mitogen-activated protein kinases.
  • Fasudil
    Fasudil hydrochloride (INN) is a potent Rho-kinase inhibitor and vasodilator.
  • Ceritinib
    Ceritinib (trade name Zykadia) is a drug for the treatment of a specific type of lung cancer.
  • Linsitinib
    Linsitinib is an experimental drug candidate for the treatment of various types of cancer.
  • Ripasudil
    Ripasudil (trade name Glanatec) is a drug used for the treatment of glaucoma and ocular hypertension.
  • Binimetinib
    Binimetinib (MEK162, ARRY-162) is a MEK inhibitor being developed by Array Biopharma to treat various cancers.
  • Palbociclib
    Palbociclib (codenamed PD-0332991, trade name Ibrance) is a drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer.
  • Staurosporine
    Staurosporine (antibiotic AM-2282 or STS) is a natural product originally isolated in 1977 from the bacterium Streptomyces staurosporeus.
  • PP2 (kinase inhibitor)
    PP2 is a substance that has frequently been used in cancer research as a "selective" inhibitor for Src-family kinases.
  • Masitinib
    Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs.
  • Balanol
    Balanol is a fungal metabolite produced by the fungus Verticillium balanoides.
  • Cobimetinib
    Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech.
  • H-89
    H-89 is a Protein kinase A inhibitor that also inhibits several other kinases (IC50 values are 80, 120, 135, 270, 2600 and 2800 nM for S6K1, MSK1, PKA, ROCKII, PKBα and MAPKAP-K1b).
  • Alisertib
    Alisertib (MLN8237) is an orally available selective aurora A kinase inhibitor developed by Takeda.